Clinical Trial Update: Autologous Dendritic Cell Vaccination in Mesothelioma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating an autologous dendritic cell vaccine for malignant pleural mesothelioma has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• Autologous dendritic cell vaccine (dendritic cell vaccine)

Snippet

Sponsor: University Hospital, Antwerp | Conditions: Malignant Pleural Mesothelioma | Phase 1, Phase 2 | Status: COMPLETED